[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Center for Eye Research Australia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":154},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,74,103,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":34,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100634883","retinal-hyperspectral-imaging-in-neurodegenerative-diseases-100634883",false,"NCT07545473","Retinal Hyperspectral Imaging in Neurodegenerative Diseases","Inclusion Criteria:\n\n1. Aged over 30 years.\n2. Have dementia or a neurodegenerative disease such as Alzheimer's disease, Parkinson's disease, Lewy body dementia, Niemann-Pick type 2 or vascular dementia (age-matched and sex-matched controls will also be recruited).\n3. With the exception of participants with Parkinson's disease and Lewy body disease, for whom clinical examination by a neurologist is sufficient to establish a clinical diagnosis of probable dementia with Lewy Body or probable Parkinson disease dementia, all participants must have previously undergone at least of one of the following tests to help to confirm a clinical diagnosis of dementia or neurodegenerative disease: genetic tests, blood biomarker tests (amyloid, tau, neurofilament light), a brain amyloid beta PET scan, or cerebrospinal fluid tests.\n4. Have a minimum best corrected visual acuity level of 6\u002F60 in both eyes and no major eye problems, such as advanced age-related macular degeneration, advanced glaucoma, or greater than moderate non-proliferative diabetic retinopathy.\n5. Be willing to participate in the study and attend the Centre for Eye Research Australia.\n6. Be accompanied by a friend or family member.\n\nExclusion Criteria:\n\n1. Inability to provide informed consent\n2. Ocular conditions preventing adequate retinal imaging (e.g., dense cataract, severe corneal opacity, vitreous haemorrhage)\n3. Known contraindication to pharmacological pupil dilation\n4. Any condition that, in the investigator's opinion, would compromise participant safety or image quality",true,"ALL","30 Years",{"count":19,"type":20},930,"ESTIMATED","INTERVENTIONAL",[23],"NA","Hyperspectral retinal imaging is a non-invasive imaging modality in which a series of images of the retina are captured using light of different wavelengths. The resulting \"hypercube\" of data provides a wealth of information about the retinal structure. Our group has developed evidence supporting a role for this technology in the detection of retinal amyloid beta in Alzheimer's disease. We are undertaking further studies to establish the role of this method in the assessment of people with dementia, or those at risk of Alzheimer's disease. In addition, we wish to test whether the approach may have value in other forms of dementia or neurodegenerative disease such as Parkinson's disease, Lewy-Body dementia or vascular dementia.",[26,27,28,29,30,31,32,33],"Dementia","Neurodegenerative Diseases","Alzheimer Disease","Parkinson Disease","Frontotemporal Dementia","Vascular Dementia","Lewy Body Disease","Niemann-Pick Diseases",[35,36],"Hyperspectral imaging","Retina","RECRUITING","2026-04-21",{"date":40,"type":41},"2026-04-22","ACTUAL",{"date":43,"type":41},"2021-10-11",{"date":45,"type":20},"2028-12-31",{"name":47,"class":48},"Center for Eye Research Australia","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":15,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":49},"100635660","defining-retinal-structures-using-hyperspectral-retinal-imaging-100635660","NCT07555574","Defining Retinal Structures Using Hyperspectral Retinal Imaging","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Able to provide informed consent\n* Willing and able to attend a study visit at the Centre for Eye Research Australia\n* Participants with diagnosed retinal or optic nerve disease (e.g., diabetic retinopathy, glaucoma, age-related macular degeneration)\n* Age- and sex-matched healthy control participants without known retinal or optic nerve disease\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Ocular conditions preventing adequate retinal imaging (e.g., dense cataract, severe corneal opacity, vitreous haemorrhage)\n* Known contraindication to pharmacological pupil dilation\n* History of narrow anterior chamber angle or risk of angle closure glaucoma where dilation is considered unsafe\n* Any condition that, in the investigator's opinion, would compromise participant safety or image quality","18 Years",{"count":58,"type":20},1000,[23],"This study evaluates hyperspectral retinal imaging as a novel, non-invasive imaging technique to characterise retinal and optic nerve structures in healthy individuals and patients with eye disease. Hyperspectral imaging captures retinal data across multiple wavelengths to generate detailed spectral information that may reveal features not visible with conventional retinal photography.\n\nApproximately 1000 participants will undergo multi-modal ophthalmic imaging in Melbourne, Australia, including hyperspectral imaging, OCT, fundus photography, and related tests. The study aims to compare hyperspectral imaging with standard imaging methods and assess its ability to identify retinal biomarkers associated with diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration.",[62,63,64,65,66],"Age-Related Macular Degeneration","Diabetic Retinopathy","Glaucoma","Retinal Diseases","Healthy Volunteers",{"date":68,"type":41},"2026-04-29",{"date":70,"type":41},"2025-01-01",{"date":72,"type":20},"2028-12-30",{"name":47,"class":48},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":5},"100561267","phase-4-nicotinamide-riboside-oral-supplementation-in-macula-off-retinal-detachment-100561267","NCT06587945","Nicotinamide Riboside Oral Supplementation in Macula Off Retinal Detachment","A Randomised Double-Masked Placebo-Controlled Trial of Nicotinamide Riboside Oral Supplementation in Macula Off Retinal Detachment","NOMAD","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Able to give informed consent and comply with all study visits and procedures.\n* Present within 10 days of macula-off retinal detachment (based on patient-reported history of loss of central vision)\n* Present to the hospital with a visual acuity of hand motion or better in the study eye\n* Have had previous cataract surgery in the study eye\n* Have clinical indication for standard retinal reattachment surgery by means of a pars plana vitrectomy and gas tamponade\n* In the opinion of the investigator, be able to safely undergo all study procedures.\n\nKey exclusion Criteria:\n\n* Any known significant ocular disease in the study eye (e.g., cornea opacity) which, in the opinion of the investigator, would preclude a visual acuity of at least 6\u002F7.5 (20\u002F25) following successful vitrectomy or limit adequate visibility of the retina.\n* Any other ocular pathology in the study eye requiring treatment with topical ophthalmic drops or intravitreal injection.\n* History of previous ocular surgery in the study eye other than uncomplicated cataract surgery with posterior chamber intraocular lens and intact posterior capsule or a refractive surgery (surgery must have occurred at least 3 months prior to the baseline visit).\n* Participation in other clinical trials or use of any other investigational drugs or devices within 3 months prior to study participation.\n* Females who are pregnant or lactating and women of childbearing potential.\n* Known retinopathy, known hepatic disease (or history of significant chronic liver disease), or known renal disease. Patients Participants with diabetes and no known retinopathy may be enrolled.\n* History of uncontrolled hypertension.\n* History of stroke, transient ischemic attack, or major cardiac surgery within 3 months prior to study, or current treatment for systemic infection.\n* Any ocular or systemic condition that in the opinion of the investigator could compromise the safety of the patientparticipant, or may interfere with the safety and tolerability assessments or study procedures of the trial.",{"count":83,"type":20},144,[85],"PHASE4","Retinal detachment occurs when fluid separates the retina (a thin, light sensing tissue) from its usual attachment at the back of the eye. If detached, these retinal cells lose their normal blood supply and begin to die, which is the primary cause of vision loss in retinal detachment. The 'macula' refers to the very centre of the retina, with the highest density of retinal cells, most responsible for vision. Significant vision loss occurs when this part of the retina becomes separated (termed a 'macula-off retinal detachment'). Typically, surgery is required to repair the retinal detachment.\n\nSupporting the health of retinal cells at the macula may prolong their survival after detachment and their recovery postoperatively. Recent evidence has shown that boosting our nicotinamide adenine dinucleotide (NAD+) levels may improve the health of these cells and prolong their survival if detached. Oral Nicotinamide Riboside (NR) is converted into NAD+, and while not studied for macula-off retinal detachments, has been safely used in a range of other conditions. This study is designed to help evaluate the safety and tolerability of NR to help preserve vision in people diagnosed with macula-off retinal detachment.\n\nThis study drug is given as an oral supplement (tablet) at the time of retinal detachment diagnosis, and daily for 20 weeks thereafter. The drug aims to prolong survival of cells in the retina (and macula) and their recovery after surgery.\n\nThe long-term goal of this treatment is to reduce loss of vision after retinal detachment. The researchers will compare NR to a placebo (a look-alike substance that contains no drug) to see if NR has a positive effect on photoreceptor survival and quality of vision postoperatively.\n\nNR has been approved by the Therapeutic Goods Administration in Australia for many purposes but has not been approved for use in retinal detachment treatment.",[88],"Retinal Detachment",[90,91,92,93,94],"Nicotinamide Riboside","Retinal detachment","Photoreceptors","Macula-off","Vitrectomy","2026-03-19",{"date":97,"type":41},"2026-03-23",{"date":99,"type":41},"2025-09-19",{"date":101,"type":20},"2028-03-30",{"name":47,"class":48},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":49},"100585883","functional-assessments-in-vision-impairment-100585883","NCT06908161","Functional Assessments in Vision Impairment","A Novel Approach for Capturing Real-world Functional Assessment Outcomes in Participants With a Vision Impairment","Inclusion Criteria:\n\n1. Willing to provide signed informed consent.\n2. Be available for study visits.\n3. Willing to comply with study assessments.\n4. In good general health and ambulant.\n5. Aged over 18 years of age.\n6. Have a vision impairment caused by any ocular condition which affects independent mobility.\n7. Agree to allow the research team into their home and local environments.\n8. Participate in assessments in public settings\n\nExclusion Criteria:\n\n1. Significant co-morbidities which prohibit involvement in study visits.\n2. Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.\n3. Cognitive deficiencies, including dementia or progressive neurological disease.\n4. Have a psychiatric condition that, in the investigator's opinion, precludes compliance with the protocol including past or present psychoses and bipolar disorder.\n5. Deafness or significant hearing loss.\n6. Inability to converse in English.",{"count":111,"type":20},45,"OBSERVATIONAL","The aim of the research project is to validate the use of a novel functional assessment tool designed to document how participants with a vision impairment complete activities of daily living in a real world environment.",[115,116,117,64,118],"Retinitis Pigmentosa (RP)","Diabetic Retinopathy (DR)","Age Related Macular Degeneration (AMD)","Retinal Dystrophy","NOT_YET_RECRUITING","2025-03-26",{"date":122,"type":41},"2025-04-03",{"date":124,"type":20},"2025-04-01",{"date":126,"type":20},"2027-12-31",{"name":47,"class":48},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":15,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":137,"conditions":138,"keywords":143,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":49},"100419253","project-amd-comprehensive-characterisation-of-age-related-macular-degeneration-and-its-progression-100419253","NCT04739319","Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression","Project AMD","Inclusion Criteria:\n\n1. 18 years of age or older; and\n2. either AMD (defined as having at least a medium druse \\>63 um), or having eyes with normal ageing changes (including small drusen ≤63 um) or no abnormalities as control participants\n\nExclusion Criteria:\n\n1. ocular or systemic conditions other than AMD that could compromise retinal assessment or assessment of AMD and its progression; or\n2. any participant with any mental or physical impairment that prevents them from signing an informed consent form or participating in this study.",{"count":136,"type":20},2500,"Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss worldwide, and nearly two million Australians have some signs of AMD. This proposed project is a prospective, observational study that seeks to to understand the underlying aetiology of AMD, factors associated with differences between age-related macular degeneration (AMD) phenotypes or severities, or between AMD and healthy individuals. It also seeks to understand the natural history of AMD progression and the factors associated with the rate of progression. In this project, the disease phenotype, genotype and severity and rate of progression will be determined based on non-invasive clinical imaging or functional assessment of the retina, from obtaining biological samples from the participants, or from patient-reported outcomes.",[139,140,141,142],"Age Related Macular Degeneration","Geographic Atrophy","AMD","Age-related Macular Degeneration",[139,140,144,145],"Drusen","Macular disease","2024-02-07",{"date":148,"type":41},"2024-02-09",{"date":150,"type":41},"2021-02-02",{"date":152,"type":20},"2040-11",{"name":47,"class":48},""]